Adjuvant therapy for postmenopausal ER-positive breast cancer. Why tamoxifen still has a future? The Leuven point of view.
Neven P, Paridaens R, Amant F, Wildiers H, Berteloot P, Leunen K, Smeets A, Weltens C, van den Bogaert W, van Limbergen E, Christiaens MR, Vergote I.
Neven P, et al. Among authors: leunen k.
Int J Gynecol Cancer. 2006;16 Suppl 2:505-10. doi: 10.1111/j.1525-1438.2006.00682.x.
Int J Gynecol Cancer. 2006.
PMID: 17010059
Review.
No abstract available.